Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2018 pp 587–609Cite as

Magen-Darm-Mittel und Lebertherapeutika

  • Chapter

Zusammenfassung

Bedeutsamste Gruppe der Magen-Darm-Mittel sind wie in den vergangenen Jahren die Protonenpumpeninhibitoren (PPI), die 2017 trotz leicht rückläufiger Verordnungen weiterhin mit großem Abstand vor allen anderen Präparategruppen liegen. Der Rückgang der Verordnungen einiger der neu entwickelten Medikamente, mit denen eine chronische Hepatitis C geheilt werden kann, bedarf der gesonderten Betrachtung. Verordnungen der Prokinetika Metoclopramid und Domperidon sind weiter rückläufig im Gegensatz zu Prucaloprid. Bei Medikamenten gegen chronischentzündliche Darmkrankheiten ist eine weitere Zunahme der Verschreibung des Integrin-Inhibitors Vedolizumab zu verzeichnen ebenso bei Pankreatinpräparaten. Kleinere Verordnungsvolumina entfallen Spasmolytika, Antidiarrhoika und Laxantien.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2009): Arzneiverordnungen. Empfehlungen zur rationalen Pharmakotherapie. 22. Auflage, Medizinische Medien Informations GmbH (MMI) Neu-Isenburg, S. 823–835

    Google Scholar 

  • Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP (2010): Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362: 1071–1081

    Google Scholar 

  • Besselink MG, van Santvoort HC, Buskens E, Boermeester MA, van Goor H, Timmerman HM, Nieuwenhuijs VB, Bollen TL, van Ramshorst B, Witteman BJ, Rosman C, Ploeg RJ, Brink MA, Schaapherder AF, Dejong CH, Wahab PJ, van Laarhoven CJ, van der Harst E, van Eijck CH, Cuesta MA, Akkermans LM, Gooszen HG; Dutch Acute Pancreatitis Study Group (2008): Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebocontrolled trial. Lancet; 371: 651–659

    Google Scholar 

  • Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343: 1520–1528

    Google Scholar 

  • Bour B, Staub JL, Chousterman M, Labayle D, Nalet B, Nouel O, Pariente A, Tocque E, Bonnot-Marlier S (2005): Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment. Aliment Pharmacol Ther 21: 805–812

    Google Scholar 

  • Bouras EP, Scolapio JS (2004): Gastric motility disorders: management that optimizes nutritional status. J Clin Gastroenterol 38: 549–557

    Google Scholar 

  • Camilleri M, Kerstens R, Rykx A, Vandeplassche L (2008): A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med 358: 2344–2354

    Google Scholar 

  • Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ (2002): Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110

    Google Scholar 

  • Chan FK, Ching JY, Hung LC, Wong VW, Leung VK, Kung NN, Hui AJ, Wu JC, Leung WK, Lee VW, Lee KK, Lee YT, Lau JY, To KF, Chan HL, Chung SC, Sung JJ (2005): Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 352: 238–244

    Google Scholar 

  • Corley DA, Kubo A, Zhao W, Quesenberry C (2010): Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology 139: 93–101

    Google Scholar 

  • Depta JP, Bhatt DL (2012): Antiplatelet therapy and proton pump inhibition: cause for concern? Curr Opin Cardiol 27:642–650

    Google Scholar 

  • De Vrese M, Marteau PR (2007): Probiotics and prebiotics: effects on diarrhea. J Nutr 137 (3 Suppl 2): 803S–811S

    Google Scholar 

  • Emmanuel AV, Kamm MA, Roy AJ, Kerstens R, Vandeplassche L (2012): Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction – a double-blind, placebo-controlled, cross-over, multiple n = 1 study. Aliment Pharmacol Ther 35: 48–55

    Google Scholar 

  • Feagan BG, Sandborn WJ, Lazar A, Thakkar RB, Huang B, Reilly N, Chen N, Yang M, Skup M, Mulani P, Chao J (2014): Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis. Gastroenterology 146: 110–118

    Google Scholar 

  • Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group (2016): Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 375: 1946–1960

    Google Scholar 

  • Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S; ASTRAL-1 Investigators (2015): Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373: 2599–2607

    Google Scholar 

  • Fischbach W, Malfertheiner P, Jansen PL, Bolten W, Bornschein J, Buderus S, Glocker E, Hoffmann JC, Koletzko S, Labenz J, Mayerle J, Miehlke S, Mössner J, Peitz U, Prinz C, Selgrad M, Suerbaum S, Venerito M, Vieth M (2016): Helicobacter pylori: S2k-Leitlinie Helicobacter pylori und gastroduodenale Ulkuskrankheit. Z Gastroenterol 54: 327–362

    Google Scholar 

  • Ford AC, Moayyedi P, Lacy BE, Lembo AJ, Saito YA, Schiller LR, Soffer EE, Spiegel BM, Quigley EM; Task Force on the Management of Functional Bowel Disorders (2014): American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol 109 Suppl 1: S2–26

    Google Scholar 

  • Freedberg DE, Kim LS, Yang YX (2017): The risks and benefits of long-term use of proton pump inhibitors: Expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 152: 706–715

    Google Scholar 

  • Gemeinsame Prüfeinrichtungen Baden-Württemberg (2016): Therapiehinweis zur wirtschaftlichen Behandlung der chronischen Hepatitis C: Internet: http://www.gpe-bw.de/facharztgruppen/fachaerztliche-internisten/hepatitis-c/

  • Gemeinsame Prüfeinrichtungen Baden-Württemberg (2017): Therapiehinweis zur wirtschaftlichen Behandlung der chronischen Hepatitis C: Internet: http://www.gpe-bw.de/facharztgruppen/fachaerztliche-internisten/hepatitis-c/

  • Gong Y, Huang ZB, Christensen E, Gluud C (2008): Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2008; Cd000551

    Google Scholar 

  • Halm U, Löser C, Löhr M, Katschinski M, Mössner J (1999): A double-blind, randomized, multicentre, crossover study to prove equivalence of pancreatin minimicrospheres versus microspheres in exocrine pancreatic insufficiency. Aliment Pharmacol Ther 13: 951–957

    Google Scholar 

  • Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH (2004): Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127: 723–729

    Google Scholar 

  • Hellers G, Cortot A, Jewell D, Leijonmarck CE, Löfberg R, Malchow H, Nilsson LG, Pallone F, Pena S, Persson T, Prantera C, Rutgeerts P (1999): Oral budesonide for prevention of postsurgical recurrence in Crohn’s disease. Gastroenterology 116: 294–300

    Google Scholar 

  • Hoffmeister A, Mayerle J, Beglinger C, Büchler MW, Bufler P, Dathe K, Fölsch UR, Friess H, Izbicki J, Kahl S, Klar E, Keller J, Knoefel WT, Layer P, Loehr M, Meier R, Riemann JF, Rünzi M, Schmid RM, Schreyer A, Tribl B, Werner J, Witt H, Mössner J, Lerch MM (2012): S3-Leitlinie Chronische Pankreatitis: Definition, Ätiologie, Diagnostik, konservative, interventionell endoskopische und operative Therapie der chronischen Pankreatitis. Leitlinie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS). Z Gastroenterol 50: 1176–1224

    Google Scholar 

  • Kark W, Krebs-Richter H, Hotz J (1995): Improving the effect of orthograde colonic lavage with golytely solution by adding dimethicone. Z Gastroenterol 33: 20–23

    Google Scholar 

  • Kassenärztliche Bundesvereinigung (2011): Verordnungsfähigkeit von Resolor®. Informationen für die Pharmakotherapieberater der KVen. Schreiben vom 11. Februar 2011

    Google Scholar 

  • Kimer N, Krag A, Møller S, Bendtsen F, Gluud LL (2014): Systematic review with meta-analysis: the effects of rifaximin in hepatic encephalopathy. Aliment Pharmacol Ther 40: 123–132

    Google Scholar 

  • Koop H, Fuchs KH, Labenz J, Lynen Jansen P, Messmann H, Miehlke S, Schepp W, Wenzl TG; Mitarbeiter der Leitliniengruppe. S2k-Leitlinie (2014): Gastroösophageale Refluxkrankheit unter Federführung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) AWMF Register Nr. 021-013 Z Gastroenterol 52: 1299–1346

    Google Scholar 

  • Koop H (2018) Verordnungspraxis und Risiken von Protonenpumpenblockern – Fiktion und Fakten? Z Gastroenterol 56: 264–274

    Google Scholar 

  • Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J (2004): Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53: 1617–1623

    Google Scholar 

  • Kwo P, Gane EJ, Peng CY, Pearlman B, Vierling JM, Serfaty L, Buti M, Shafran S, Stryszak P, Lin L, Gress J, Black S, Dutko FJ, Robertson M, Wahl J, Lupinacci L, Barr E, Haber B (2017): Effectiveness of elbasvir and grazoprevir combination, with or without ribavirin, for treatment-experienced patients with chronic hepatitis C infection. Gastroenterology 152: 164–175

    Google Scholar 

  • Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Schutze K, Wallner G, Juergens H, Preiksaitis H, Keeling N, Naucler E, Adler J, Eklund S (2005): Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther 22: 803–811

    Google Scholar 

  • Lam JR, Schneider JL, Zhao W, Corley DA (2013): Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA 310: 2435–1542

    Google Scholar 

  • Layer P, Andresen V, Pehl C, Allescher H, Bischoff SC, Classen M, Enck P, Frieling T, Haag S, Holtmann G, Karaus M, Kathemann S, Keller J, Kuhlbusch-Zicklam R, Kruis W, Langhorst J, Matthes H, Mönnikes H, Müller-Lissner S, Musial F, Otto B, Rosenberger C, Schemann M, van der Voort I, Dathe K, Preiss JC (2011): S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie. Z Gastroenterol 49: 237–293

    Google Scholar 

  • Lee-Robichaud H, Thomas K, Morgan J, Nelson RL (2010): Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev 2010 Jul 7; (7): CD007570

    Google Scholar 

  • Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D,Hunt R, Rokkas T, Vakil N, Kuipers EJ (2007): Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56: 772–781

    Google Scholar 

  • Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group (2011): Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycinbased triple therapy: a randomised, open-label, noninferiority, phase 3 trial. Lancet 377: 905–913

    Google Scholar 

  • Malfertheiner P, Megraud F, O’Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ; European Helicobacter Study Group (2012): Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 61: 646–664

    Google Scholar 

  • Metcalf TJ, Irons TG, Sher LD, Young PC (1994): Simethicone in the treatment of infant colic: a randomized placebocontrolled multicenter trial. Pediatrics 94: 29–34

    Google Scholar 

  • Mössner J (2016): Indikationen, Nutzen und Risiken von Protonenpumpeninhibitoren. Eine Bestandsaufnahme nach 25 Jahren. Dtsch Ärzteblatt 113: 477–483

    Google Scholar 

  • National Institute for Health and Care Excellence (2014): Dyspepsia and gastro-oesophageal reflux disease. Investigation and management of dyspepsia, symptoms suggestive of gastro-oesophageal reflux disease, or both. NICE clinical guideline 184. Internet: guidance.nice.org. uk/cg184

    Google Scholar 

  • Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group (2016): A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 375: 631–643

    Google Scholar 

  • Panaccione R, Ghosh S, Middleton S, Márquez JR, Scott BB, Flint L, van Hoogstraten HJ, Chen AC, Zheng H, Danese S, Rutgeerts P (2014): Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 146: 392–400

    Google Scholar 

  • Peura DA, Gudmundson J, Siepman N, Pilmer BL, Freston J (2007): Proton pump inhibitors: effective first-line treatment for management of dyspepsia. Dig Dis Sci 52: 983–987

    Google Scholar 

  • Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R (2007): Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45: 549–559

    Google Scholar 

  • Sandborn WJ, Korzenik J, Lashner B, Leighton JA, Mahadevan U, Marion JF, Safdi M, Sninsky CA, Patel RM, Friedenberg KA, Dunnmon P, Ramsey D, Kane S (2010): Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. Gastroenterology 138: 1286–1296

    Google Scholar 

  • Scherübl H, Fischbach W, Glocker E, Malfertheiner P (2015): Was ist neu bei der Behandlung der Helicobacter-pylori-Infektion? Dtsch Med Wochenschr 140: 277–280

    Google Scholar 

  • Schmieder G, Stankov G, Zerle G, Schinzel S, Brune K (1993): Observer-blind study with metamizole versus tramadol and butylscopolamine in acute biliary colic pain. Arzneim Forsch 43: 1216–1221

    Google Scholar 

  • Siegmund E, Löhr JM, Schuff-Werner P (2004): Die diagnostische Validität nichtinvasiver Pankreasfunktionstests - Eine Metaanalyse. Z Gastroenterol 42: 1117–1128

    Google Scholar 

  • Sjöstedt S, Befrits R, Sylvan A, Harthon C, Jörgensen L, Carling L, Modin S, Stubberöd A, Toth E, Lind T (2005): Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 22: 183–191

    Google Scholar 

  • Smith DS, Ferris CD (2003): Current concepts in diabetic gastroparesis. Drugs 63: 1339–1358

    Google Scholar 

  • Stedman CA, Barclay ML (2000): Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 14: 963–978

    Google Scholar 

  • Sudduth RH, DeAngelis S, Sherman KE, McNally PR (1995): The effectiveness of simethicone in improving visibility during colonoscopy when given with a sodium phosphate solution: a double-bind randomized study. Gastrointest Endosc 42: 413–415

    Google Scholar 

  • Szajewska H, Horvath A, Piwowarczyk A (2010): Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther 32: 1069–1079

    Google Scholar 

  • Trépo C, Chan HL, Lok A (2014): Hepatitis B virus infection. Lancet 384: 2053–2063

    Google Scholar 

  • Tromm A, Bunganič I, Tomsová E, Tulassay Z, Lukáš M, Kykal J, Bátovský M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Löhr H, Koutroubakis I, Bar-Meir S, Stimac D, Schäffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R; International Budenofalk Study Group (2011): Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn’s disease. Gastroenterology 140: 425–434

    Google Scholar 

  • Ueberschaer H, Allescher HD (2017): Protonenpumpenhemmer - Nebenwirkungen und Komplikationen der langfristigen Protonenpumpenhemmereinnahme. Z Gastroenterol 55: 636–674

    Google Scholar 

  • van Zanten SV, Armstrong D, Chiba N, Flook N, White RJ, Chakraborty B, Gasco A (2006): Esomeprazole 40 mg once a day in patients with functional dyspepsia: the randomized, placebo-controlled „ENTER” trial. Am. J Gastroenterol 101: 2096–2106. Erratum in: Am J Gastroenterol 101: 2171

    Google Scholar 

  • Webster DP, Klenerman P, Dusheiko GM (2015): Hepatitis C. Lancet 385: 1124–1135

    Google Scholar 

  • Wolfe MM, Lichtenstein DR (1999): Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340: 1888–1899

    Google Scholar 

  • Wu D, Wu SM, Lu J, Zhou YQ, Xu L, Guo CY (2013): Rifaximin versus nonabsorbable disaccharides for the treatment of hepatic encephalopathy: A Meta-Analysis. Gastroenterol Res Pract 2013: 236963 doi: 10.1155/2013/236963

  • Zimmermann T, Jansen PL, Sarrazin C, Vollmar J, Zeuzem S (2018): S3-Leitlinie „Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus (HCV) -Infektion“. Z Gastroenterol 56: e53-e115

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Universitätsklinikum Leipzig, Liebigstraße 20, 04103, Leipzig, Deutschland

    Joachim Mössner

Authors
  1. Joachim Mössner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg, Deutschland

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln, Deutschland

    Dieter Paffrath

  3. Arzneimittelkommission der deutschen Ärzteschaft, Herbert-Lewin-Platz 1, 10623, Berlin, Deutschland

    Wolf-Dieter Ludwig

  4. Wissenschaftliches Institut der AOK (WIdO), Rosenthaler Straße 31, 10178, Berlin, Deutschland

    Jürgen Klauber

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Cite this chapter

Mössner, J. (2018). Magen-Darm-Mittel und Lebertherapeutika. In: Schwabe, U., Paffrath, D., Ludwig, WD., Klauber, J. (eds) Arzneiverordnungs-Report 2018. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-57386-0_33

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-57386-0_33

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-57385-3

  • Online ISBN: 978-3-662-57386-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation